Loading quotes...
Forecast
The analysts' average price target is €16.54 (+90.33%). The median is €10.91 (+25.55%).
| Buy |
3 |
| Hold |
5 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
iTeos Therapeutics acquired by Concentra and delisted from Nasdaq
iTeos Therapeutics became a wholly owned subsidiary of Concentra Biosciences through a merger and its shares were delisted from the Nasdaq; shareholders received USD 10.047 in cash plus a contingent value right (CVR). All merger conditions were met, about 72.17% of outstanding shares were tendered, the board of directors of iTeos resigned and leadership positions were filled by representatives of Concentra Merger Sub VIII, Inc. Leerink Partners cut its price target for iTeos in light of the takeover; the company intends to terminate its SEC registration. » More on de.investing.com
Financials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -66.8m | - |
| EBITDA | -56.15m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €407.83m |
Number of shares | 44.21m |
52-week high/low | €16.02 - €4.36 |
| Dividends | No |
Beta | 1.49 |
P/E ratio | -3.06 |
PEG ratio | 0.06 |
P/B ratio | 0.70 |
P/S ratio | 12.82 |
Company profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
| Name | iTeos Therapeutics |
| CEO | Michel Detheux |
| Headquarters | Watertown,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 24/07/2020 |
| Employees | 173 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ITOS |